MacroGenics Announces Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab

Go back to MacroGenics Announces Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab
MACROGENICS (NASDAQ: MGNX) Delayed: 4.78 --0 (-0%)
Previous Close $4.78    52 Week High $36.11 
Open $4.78    52 Week Low $14.84 
Day High $4.78    P/E 12.26 
Day Low $4.78    EPS $0.39 
Volume 303